ALG11-CDG: Novel variant and review of the literature
Journal of Pediatric Endocrinology and Metabolism, vol.36, no.4, pp.409-413, 2023 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 36 Issue: 4
- Publication Date: 2023
- Doi Number: 10.1515/jpem-2022-0480
- Journal Name: Journal of Pediatric Endocrinology and Metabolism
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, MEDLINE
- Page Numbers: pp.409-413
- Keywords: ALG11-CDG, carbohydrate-deficient transferrin, epileptic encephalopathy
- Ankara Yıldırım Beyazıt University Affiliated: Yes
Abstract
Objectives: Asparagine-dependent glycosylation 11-congenital disorders of glycosylation (ALG11-CDG) is a rare autosomal recessive N-glycosylation defect with multisystem involvement particularly neurological symptoms such as epilepsy and neuromotor developmental delay. Case presentation: A 31-month-old male patient admitted to our center with complaints of axial hypotonia, drug-resistant myoclonic seizures, microcephaly and deafness. The electroencephalography (EEG) showed a burst-suppression pattern without hypsarrhythmia. Basal metabolic investigations were unremarkable. Progressive cerebral atrophy, hypomyelination and corpus callosum hypoplasia were striking features in brain MRI images taken during our follow-up. Compound heterozygous mutations of the ALG11 gene were found by whole exome sequencing (WES) analysis. It was determined that the c.476T>C mutation is a novel mutation. CDG type 1 pattern was detected with the examination of carbohydrate-deficient transferrin (CDT) by capillary zone electrophoresis. Conclusions: In patients with a possible congenital defect of glycosylation, a screening test such as CDT analysis is suggested. To discover novel mutations in this rare disease group, expanded genetic analysis should be performed.